Patent · US Active

Transgenic insect cells comprising a bacterial GlcNAc-6-P 2′-epimerase

US9816107B2 · kind B2 · utility

0Cited by
4References
33Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 14, 2013
Grant dateNov 14, 2017
Priority date
Expiry dateMay 14, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2710/14043
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present invention relates to methods of facilitating the expression of recombinant polypeptides from cells, extracellular fluids, extracellular fibers, or any combination thereof, obtained from transgenic insect cells and larvae comprising a bacterial GlcNAc-6-P 2′-epimerase (GNPE), which is capable of converting N-acetyl-D-glucosamine-6-phosphate (GlcNAc-6-P) to N-acetyl-D-mannosamine-6-phosphate (ManNAc-6-P). The invention relates to methods to promote efficient glycoconjugate sialylation, by providing simpler ways to produce large intracellular pools of sialic acid precursors. The invention is also directed to nucleic acids, vectors, and cells comprising nucleic acids encoding polypeptides involved in the synthesis of sialic acid precursors, and cells in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins. The engineered cells can be used to produce glycosylated proteins lepidopteran insects and cultured cell lines derived from Spodoptera frugiperda, Trichoplusia ni, and silkworms, such as Bombyx mori, particularly those that can be infected by baculovirus expression v…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.